Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Definium Therapeutics, Inc.MNMD · Entity 3884 | Director | June 01, 2022 | June 06, 2022 |
| ELUTIA INC.ELUT · Entity 7342 | Director | June 11, 2026 | June 15, 2026 |
| Quantum-Si IncQSI · Entity 6440 | Director | May 18, 2026 | May 20, 2026 |
| Vivani Medical, Inc.VANI · Entity 6636 | Chief Financial Officer | May 12, 2025 | May 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Definium Therapeutics, Inc.
Report date June 01, 2022 · Filed June 06, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Subordinate Voting SharesSEC Table I · non-derivative | Direct | 158,706 |
Reported balance
After 2022-06-01 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2022-06-01 · Grant · Acquired 64,656 · Balance 158,706 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. The RSUs vest in equal installments over 36 months beginning on June 1, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2027-05-31 | Direct | 194,358 |
Reported balance
After 2022-06-01 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2022-06-01 · Grant · Acquired 100,308 · Balance 194,358 F2: The option grant has an exercise price of $0.75 Canadian Dollars. This represents the exercise price in United States Dollars. F3: 1/3rd of the shares underlying the option vest and become exercisable on June 1, 2023; the remaining 2/3rds of the shares underlying the option shall vest in equal installments, vesting at the end of each month thereafter for the succeeding 24 months, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. |
| Director's Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 643,804 |
Reported balance
After 2022-06-01 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2022-06-01 · Grant · Acquired 361,680 · Balance 643,804 F4: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3 vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. The RSUs vest in equal installments over 36 months beginning on June 1, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date.
F2: The option grant has an exercise price of $0.75 Canadian Dollars. This represents the exercise price in United States Dollars.
F3: 1/3rd of the shares underlying the option vest and become exercisable on June 1, 2023; the remaining 2/3rds of the shares underlying the option shall vest in equal installments, vesting at the end of each month thereafter for the succeeding 24 months, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date.
F4: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3 vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan).
ELUTIA INC.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2036-06-11 | Direct | 106,393 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 106,393 · Balance 106,393 F1: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date.
Quantum-Si Inc
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.85 · Expires 2036-05-18 | Direct | 251,185 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Grant · Acquired 251,185 · Balance 251,185 F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date. |
| Class A Common StockSEC Table I · non-derivative | Direct | 20,512 |
Reported balance
Holding disclosure · report date 2026-05-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,512 |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date.
Vivani Medical, Inc.
Report date May 12, 2025 · Filed May 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2035-05-11 | Direct | 75,000 |
Reported balance
After 2025-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-12 · Grant · Acquired 75,000 · Balance 75,000 F1: The stock options have a 10-year term and vest 25% at one-year and monthly thereafter for 36 months, subject to the Reporting Person's continued service through each applicable vesting date. |
| RSUsSEC Table II · derivative / convertible security | Direct | 37,500 |
Reported balance
After 2025-05-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-12 · Grant · Acquired 37,500 · Balance 37,500 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Vivani common stock. F3: The performance based RSUs shall vest in three stages: one-third when the stock price closes at or above $3.15 for three consecutive days, another one-third one year after this date when the market condition is first achieved, and the final one-third one year after this second vesting date when the market condition is achieved, subject to the Reporting Person's continued service through each applicable vesting date. If the RSUs fail to close at or above $3.15 for three consecutive trading dates within a four year term from the date of the grant, the RSUs shall expire. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options have a 10-year term and vest 25% at one-year and monthly thereafter for 36 months, subject to the Reporting Person's continued service through each applicable vesting date.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Vivani common stock.
F3: The performance based RSUs shall vest in three stages: one-third when the stock price closes at or above $3.15 for three consecutive days, another one-third one year after this date when the market condition is first achieved, and the final one-third one year after this second vesting date when the market condition is achieved, subject to the Reporting Person's continued service through each applicable vesting date. If the RSUs fail to close at or above $3.15 for three consecutive trading dates within a four year term from the date of the grant, the RSUs shall expire.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 15, 2026 21:00 UTC | ELUTIA INC. ELUT · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 106,393 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001375927-26-000002 · form4-06152026_050601.xml · derivative · entry 1 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,393 Underlying: Class A Common Stock · 106,393 shares Expires 2036-06-11 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:05 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantStock Option (right to buy) · Derivative | 251,185 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001140361-26-022240 · form4.xml · derivative · entry 2 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,185 Underlying: Class A Common Stock · 251,185 shares Expires 2036-05-18 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date. Read SEC document |
| December 17, 2025 Filed Dec 18, 2025 14:00 UTC | ELUTIA INC. ELUT · Entity 7342 | PurchaseClass A Common Stock | 25,000 | $0.52 | $13,000.00 |
DisclosureSEC source: 0001375927-25-000005 · form4-12182025_091205.xml · nonDerivative · entry 1 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.51 to $0.53. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 21:00 UTC | ELUTIA INC. ELUT · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 60,339 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-25-015199 · form4-06022025_050601.xml · derivative · entry 1 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,339 Underlying: Class A Common Stock · 60,339 shares Expires 2035-05-29 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date. Read SEC document |
| May 19, 2025 Filed May 21, 2025 20:01 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantStock Option (right to buy) · Derivative | 126,095 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001140361-25-020046 · form4.xml · derivative · entry 2 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,095 Underlying: Class A Common Stock · 126,095 shares Expires 2035-05-19 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date. Read SEC document |
| May 12, 2025 Filed May 15, 2025 00:31 UTC | Vivani Medical, Inc. VANI · Entity 6636 | GrantRSUs · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001753926-25-000828 · form4.xml · derivative · entry 2 Makes Brigid · CIK 0001375927 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Vivani common stock. F3 · derivative.exercise_date: The performance based RSUs shall vest in three stages: one-third when the stock price closes at or above $3.15 for three consecutive days, another one-third one year after this date when the market condition is first achieved, and the final one-third one year after this second vesting date when the market condition is achieved, subject to the Reporting Person's continued service through each applicable vesting date. If the RSUs fail to close at or above $3.15 for three consecutive trading dates within a four year term from the date of the grant, the RSUs shall expire. F3 · derivative.expiration_date: The performance based RSUs shall vest in three stages: one-third when the stock price closes at or above $3.15 for three consecutive days, another one-third one year after this date when the market condition is first achieved, and the final one-third one year after this second vesting date when the market condition is achieved, subject to the Reporting Person's continued service through each applicable vesting date. If the RSUs fail to close at or above $3.15 for three consecutive trading dates within a four year term from the date of the grant, the RSUs shall expire. Read SEC document |
| May 12, 2025 Filed May 15, 2025 00:31 UTC | Vivani Medical, Inc. VANI · Entity 6636 | GrantCommon Stock Option · Derivative | 75,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001753926-25-000828 · form4.xml · derivative · entry 1 Makes Brigid · CIK 0001375927 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-05-11 F1 · derivative.exercise_date: The stock options have a 10-year term and vest 25% at one-year and monthly thereafter for 36 months, subject to the Reporting Person's continued service through each applicable vesting date. F1 · derivative.expiration_date: The stock options have a 10-year term and vest 25% at one-year and monthly thereafter for 36 months, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 21:00 UTC | ELUTIA INC. ELUT · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 31,835 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001415889-24-016246 · form4-06102024_050601.xml · derivative · entry 1 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,835 Underlying: Class A Common Stock · 31,835 shares Expires 2034-06-05 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:46 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantStock Option (right to buy) · Derivative | 113,281 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001140361-24-026706 · form4.xml · derivative · entry 1 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,281 Underlying: Class A Common Stock · 113,281 shares Expires 2034-05-16 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Ms. Makes' continued service through the applicable vesting date. Read SEC document |
| May 10, 2024 Filed May 14, 2024 22:48 UTC | Vivani Medical, Inc. VANI · Entity 6636 | GrantRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001753926-24-000964 · ownership.xml · derivative · entry 2 Makes Brigid · CIK 0001375927 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Vivani common stock. F3 · derivative.exercise_date: The performance based RSUs shall vest in three stages: one-third when the stock price is at or above $3.15 for three consecutive trading days, another one-third one year after this date when the market condition is first achieved, and the final one-third one year after this second vesting date when the market condition is achieved, subject to the Reporting Person's continued service through each applicable vesting date. If the RSUs fail to be at or above $3.15 for three consecutive trading dates within a four year term from the date of the grant, the RSUs shall expire. F3 · derivative.expiration_date: The performance based RSUs shall vest in three stages: one-third when the stock price is at or above $3.15 for three consecutive trading days, another one-third one year after this date when the market condition is first achieved, and the final one-third one year after this second vesting date when the market condition is achieved, subject to the Reporting Person's continued service through each applicable vesting date. If the RSUs fail to be at or above $3.15 for three consecutive trading dates within a four year term from the date of the grant, the RSUs shall expire. Read SEC document |
| May 10, 2024 Filed May 14, 2024 22:48 UTC | Vivani Medical, Inc. VANI · Entity 6636 | GrantCommon Stock Option · Derivative | 75,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001753926-24-000964 · ownership.xml · derivative · entry 1 Makes Brigid · CIK 0001375927 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-05-09 F1 · derivative.exercise_date: The stock options have a 10-year term and vest 25% at one-year and monthly thereafter for 36 months, subject to the Reporting Person's continued service through each applicable vesting date. F1 · derivative.expiration_date: The stock options have a 10-year term and vest 25% at one-year and monthly thereafter for 36 months, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| December 18, 2023 Filed Dec 19, 2023 01:27 UTC | Vivani Medical, Inc. VANI · Entity 6636 | PurchaseCommon Stock | 1,000 | $0.87 | $870.00 |
DisclosureSEC source: 0001753926-23-001593 · ownership.xml · nonDerivative · entry 2 Makes Brigid · CIK 0001375927 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on the open market. The reporting person undertakes to provide to Vivani Medical, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased in each transaction set forth in this footnote. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 01:27 UTC | Vivani Medical, Inc. VANI · Entity 6636 | PurchaseCommon Stock | 4,000 | $0.89 | $3,560.00 |
DisclosureSEC source: 0001753926-23-001593 · ownership.xml · nonDerivative · entry 1 Makes Brigid · CIK 0001375927 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 F1 · kind: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on the open market. The reporting person undertakes to provide to Vivani Medical, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased in each transaction set forth in this footnote. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 23:04 UTC | Vivani Medical, Inc. VANI · Entity 6636 | PurchaseCommon Stock | 4,000 | $0.95 | $3,780.00 |
DisclosureSEC source: 0001753926-23-001190 · ownership.xml · nonDerivative · entry 2 Makes Brigid · CIK 0001375927 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 23:04 UTC | Vivani Medical, Inc. VANI · Entity 6636 | PurchaseCommon Stock | 2,000 | $0.90 | $1,800.00 |
DisclosureSEC source: 0001753926-23-001190 · ownership.xml · nonDerivative · entry 1 Makes Brigid · CIK 0001375927 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 F1 · kind: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on the open market. The reporting person undertakes to provide to Vivani Medical, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased in each transaction set forth in this footnote. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 16:43 UTC | Vivani Medical, Inc. VANI · Entity 6636 | PurchaseCommon Stock | 3,000 | $1.21 | $3,630.00 |
DisclosureSEC source: 0001753926-23-000869 · ownership.xml · nonDerivative · entry 2 Makes Brigid · CIK 0001375927 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on the open market. The reporting person undertakes to provide to Vivani Medical, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased in each transaction set forth in this footnote. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 16:43 UTC | Vivani Medical, Inc. VANI · Entity 6636 | PurchaseCommon Stock | 1,000 | $1.24 | $1,240.00 |
DisclosureSEC source: 0001753926-23-000869 · ownership.xml · nonDerivative · entry 1 Makes Brigid · CIK 0001375927 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions on the open market. The reporting person undertakes to provide to Vivani Medical, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased in each transaction set forth in this footnote. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 15:31 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001415889-23-009586 · form4-06122023_030652.xml · derivative · entry 1 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's First Amended and Restated Non-Employee Director Compensation Policy and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date. Read SEC document |
| May 12, 2023 Filed May 16, 2023 21:01 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantStock Option (right to buy) · Derivative | 120,481 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001140361-23-025063 · form4.xml · derivative · entry 1 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,481 Underlying: Class A Common Stock · 120,481 shares Expires 2033-05-12 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Ms. Makes' continued service through the applicable vesting date. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 02:33 UTC | Vivani Medical, Inc. VANI · Entity 6636 | GrantRSUs · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001753926-23-000261 · ownership.xml · derivative · entry 2 Makes Brigid · CIK 0001375927 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-03-06 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Vivani common stock. F2 · derivative.exercise_date: The performance based RSUs vest one third when the stock price is at or above $3.15 for three consecutive business days. Second third vests one year after that. Final third vests one year after second third. If the RSUs fail to reach $3.15 for three consecutive business days within a four year term from the date of the grant the RSUs expire. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 02:33 UTC | Vivani Medical, Inc. VANI · Entity 6636 | GrantRSUs · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001753926-23-000261 · ownership.xml · derivative · entry 1 Makes Brigid · CIK 0001375927 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2027-03-06 F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Vivani common stock. F2 · derivative.exercise_date: The performance based RSUs vest one third when the stock price is at or above $3.15 for three consecutive business days. Second third vests one year after that. Final third vests one year after second third. If the RSUs fail to reach $3.15 for three consecutive business days within a four year term from the date of the grant the RSUs expire. Read SEC document |
| January 19, 2023 Filed Jan 24, 2023 02:11 UTC | Vivani Medical, Inc. VANI · Entity 6636 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001753926-23-000080 · ownership.xml · derivative · entry 2 Makes Brigid · CIK 0001375927 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-19 F1 · derivative.exercise_date: The stock options have a 10-year term and vest 25% at one year and monthly for 36 months thereafter on a equal basis. Read SEC document |
| January 19, 2023 Filed Jan 24, 2023 02:11 UTC | Vivani Medical, Inc. VANI · Entity 6636 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001753926-23-000080 · ownership.xml · derivative · entry 1 Makes Brigid · CIK 0001375927 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-19 F1 · derivative.exercise_date: The stock options have a 10-year term and vest 25% at one year and monthly for 36 months thereafter on a equal basis. Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 22:08 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 2,000 | $3.65 | $7,300.00 |
DisclosureSEC source: 0001415889-22-012417 · form4-12122022_101207.xml · nonDerivative · entry 1 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| November 07, 2022 Filed Nov 10, 2022 01:11 UTC | Vivani Medical, Inc. VANI · Entity 6636 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001753926-22-001443 · ownership.xml · derivative · entry 1 Makes Brigid · CIK 0001375927 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-11-07 F1 · derivative.exercise_date: The stock options have a 10-year term and vest monthly equally over a four-year period. F2 · derivative.underlying_shares: Awarded as compensation for serving as CFO. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 22:55 UTC | Vivani Medical, Inc. VANI · Entity 6636 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,584 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001753926-22-001276 · ownership.xml · derivative · entry 1 Makes Brigid · CIK 0001375927 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,584 Underlying: Common Stock · 13,584 shares Expires 2032-09-14 F1 · derivative.exercise_date: The stock options have a 10-year term and vest immediately. F2 · derivative.underlying_shares: Awarded as compensation for serving as CFO. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 12:34 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 22,090 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001415889-22-006334 · form4-06092022_050640.xml · derivative · entry 1 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,090 Underlying: Class A Common Stock · 22,090 shares Expires 2032-06-06 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date. Read SEC document |
| June 01, 2022 Filed Jun 4, 2022 01:22 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantDirector's Deferred Share Units · Derivative | 361,680 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-034418 · doc4.xml · derivative · entry 3 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,804 Underlying: Subordinate Voting Shares · Not disclosed shares Expires not disclosed F4 · derivative.exercise_price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3 vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3 vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.exercise_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3 vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.expiration_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3 vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.underlying: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3 vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.underlying_shares: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3 vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). Read SEC document |
| June 01, 2022 Filed Jun 4, 2022 01:22 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 100,308 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-22-034418 · doc4.xml · derivative · entry 2 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,358 Underlying: Subordinate Voting Shares · 100,308 shares Expires 2017-05-31 F2 · derivative.exercise_price: The option grant has an exercise price of $0.75 Canadian Dollars. This represents the exercise price in United States Dollars. F3 · derivative.exercise_date: 1/3rd of the shares underlying the option vest and become exercisable on June 1, 2023; the remaining 2/3rds of the shares underlying the option shall vest in equal installments, vesting at the end of each month thereafter for the succeeding 24 months, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| June 01, 2022 Filed Jun 4, 2022 01:22 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantSubordinate Voting Shares | 64,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034418 · doc4.xml · nonDerivative · entry 1 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,706 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. The RSUs vest in equal installments over 36 months beginning on June 1, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| June 01, 2022 Filed Jun 6, 2022 20:14 UTC Amendment | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantDirector's Deferred Share Units · Derivative | 361,680 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-034503 · doc4a.xml · derivative · entry 3 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,804 Underlying: Subordinate Voting Shares · Not disclosed shares Expires not disclosed F4 · derivative.exercise_price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3 vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · price: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3 vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.exercise_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3 vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.expiration_date: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3 vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.underlying: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3 vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). F4 · derivative.underlying_shares: Represents Directors' Deferred Share Units ("DDSUs") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the "Plan"), effective April 16, 2021. Of these DDSUs, 1/3 vested on June 1, 2022 and the remaining 2/3rds vest in equal installments on June 30, 2022, July 31, 2022, August 31, 2022 and September 30, 2022. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Subordinate Voting Share). Pursuant to the Plan, the fair market value of a Subordinate Voting Share is equal to the volume weighted average trading price of a Subordinate Voting Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan). Read SEC document |
| June 01, 2022 Filed Jun 6, 2022 20:14 UTC Amendment | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantStock Option (Right to Buy) · Derivative | 100,308 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-22-034503 · doc4a.xml · derivative · entry 2 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,358 Underlying: Subordinate Voting Shares · 100,308 shares Expires 2027-05-31 F2 · derivative.exercise_price: The option grant has an exercise price of $0.75 Canadian Dollars. This represents the exercise price in United States Dollars. F3 · derivative.exercise_date: 1/3rd of the shares underlying the option vest and become exercisable on June 1, 2023; the remaining 2/3rds of the shares underlying the option shall vest in equal installments, vesting at the end of each month thereafter for the succeeding 24 months, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| June 01, 2022 Filed Jun 6, 2022 20:14 UTC Amendment | Definium Therapeutics, Inc. MNMD · Entity 3884 | GrantSubordinate Voting Shares | 64,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034503 · doc4a.xml · nonDerivative · entry 1 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,706 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. The RSUs vest in equal installments over 36 months beginning on June 1, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date. Read SEC document |
| May 11, 2022 Filed May 13, 2022 20:17 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantStock Option (right to buy) · Derivative | 59,880 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001140361-22-019084 · form4.xml · derivative · entry 1 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,880 Underlying: Class A Common Stock · 59,880 shares Expires 2032-05-11 F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Ms. Makes' continued service through the applicable vesting date. Read SEC document |
| May 11, 2022 Filed May 24, 2022 20:51 UTC | Definium Therapeutics, Inc. MNMD · Entity 3884 | OtherSubordinate Voting Shares | 67,678 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031636 · doc4.xml · nonDerivative · entry 1 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,050 F1 · kind: Pro rata distribution from Savant Addition Medicine, LLC, of which the Reporting Person is a non-managing member. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 22:56 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantClass A Common Stock | 20,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-080934 · tm2119549-24_4seq1.xml · nonDerivative · entry 1 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,512 F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on June 11, 2022, subject to Ms. Makes's continued service through the applicable vesting date Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 21:46 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 14,082 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0001415889-21-002899 · form4-06092021_020621.xml · derivative · entry 1 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,082 Underlying: Class A Common Stock · 14,082 shares Expires 2031-06-06 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date. Read SEC document |
| December 09, 2020 Filed Dec 10, 2020 21:42 UTC | ELUTIA INC. AYZO · Entity 7342 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 14,307 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-20-134237 · tm2038235-1_4seq1.xml · derivative · entry 1 Makes Brigid · CIK 0001375927 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,307 Underlying: CLASS A COMMON STOCK · 14,307 shares Expires 2030-12-08 F1 · derivative.exercise_date: This option vests and becomes exercisable in three equal installments on each of October 8, 2021, 2022 and 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.